Aging is a risk factor for many age-related diseases, such as type 2 diabetes, atherosclerosis, cardiovascular pathology, cancer, retinopathy, sarcopenia, etc. With the increase in human life expectancy, there is a growing interest in the development of drugs that can delay the onset and progression of aging and age-related diseases. Anti-aging drug testing is carried out on murine models of natural aging, such as C57Bl/6N, C57Bl/6J, Balb/c, or CD-1 strains. 

Service details: A standard study design includes:

  • Groups of 25 male and 25 female mice, and the relevant group of control animals (vehicle dosed). 
  • Animals were maintained in good conventional conditions, 12-hour light/dark cycles, and free access to standardized mouse diets and acidified boiled tap water. If necessary, a calorie-restricted or modified diet is available. 
  • Treatment begins at the age of 2-3, 5-6, 10-12, or 16-18 months (at the customer’s request). 
  • The customer offers doses and schemes of treatment. 
  • Animals are maintained until natural death. Standard anti-aging effects are monitored by routine tests, such as mortality assessment (daily), body weight (weekly), physical activity (quarterly), and gross necropsy (post mortem). 
  • Specific measurements and tests, such as hematological and clinical chemistry parameters, in combination with physiological and behavioral tests and more definitive endpoints, are available for an additional cost. 
  • Treatment procedures include invasive (by IV, IP, SC, and PO routes), and non-invasive (with food) methods of drug administration. 

A typical survival curve of C57BL/6 female mice treated with metformin (M), aspirin (A), and both compounds (AM):